Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on September 17, 2025, and filed on September 18, 2025. The Company, a foreign private issuer, executed a share repurchase through its corporate stockbroker, Merrill Lynch International, pursuant to a non-discretionary agreement entered into on June 4, 2025.
Key Financial Metrics
The filing details a specific share buyback transaction rather than comprehensive financial results. Key metrics for the transaction are as follows:
- Shares Purchased: 209,886 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,461.50 GBp; highest price paid was 1,478.50 GBp.
- Average Price: Volume-weighted average price paid was 1,471.87 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Holdings: Following this purchase, the Company holds 247,448,986 ordinary shares in treasury.
- Shares in Issue: 4,067,953,982 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.08% of the total voting rights.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the commencement of the buyback programme on June 4, 2025, the Company has purchased a total of 29,314,603 ordinary shares. The specific transaction reported herein increased the treasury share count by 209,886 shares. No other material changes to the Company's financial position or operations are disclosed in this filing.
Guidance, Outlook, and Risks
The filing contains no specific guidance or outlook regarding future financial performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These factors include those described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025.
Important Facts for Investors
- Verify the total number of shares in issue (4,067,953,982) when calculating ownership percentages under Disclosure Guidance and Transparency Rules.
- Note that treasury shares (247,448,986) carry no voting rights, representing 6.08% of the total voting rights attributable to ordinary shares.
- Confirm that the buyback is ongoing under a non-discretionary agreement with Merrill Lynch International initiated on June 4, 2025.
- Review the referenced Form 20-F (2024) and Q2 2025 results for comprehensive risk factors and financial performance data not included in this transaction report.